Several methods are used to determine the variables. Most information is collected directly from patients: they will fill out questionnaires, will use an electronic monitoring pill-container and will donate blood samples. Furthermore, medical information will be retrieved from the patients' file.
Questionnaires
The patients will be asked to fill out five questionnaires spread over 16 weeks. The first questionnaire (t = 0) contains questions on patient characteristics, smoking, co-medication, side-effects, quality of life, and patients beliefs and attitude towards disease and medication. In weeks 3-4, 8-9 and 15-16 patients will be asked to fill out an elaborate questionnaire containing questions determining the adherence behaviour, side-effects, dose adjustment, co-medication, quality of life, and patients beliefs and attitude towards disease and medication. In week 12 patients are asked to fill out a short questionnaire containing only questions determining the adherence behaviour, side effects, and dose adjustment. Discontinuation and reasons for discontinuation will be asked in a short questionnaire when a patient stops the erlotinib treatment prematurely.
The questionnaires contain the following items:
1. MARS (Medication Adherence Report Scale) [
40,
41]. This questionnaire contains statements about adherence behaviour.
2. Nature and grade of the side-effects in a five-point scale.
3. Quality of life measured with SF-12 Health Survey [
42,
43]. The SF-12 is a short version of the SF-36 and is a validated method to measure quality of life.
4. Attitude towards disease measured with Brief Illness Perception Questionnaire (Brief IPQ) [
21]. The Brief IPQ is a validated method to measure the attitude towards disease.
5. Beliefs and attitude towards medicines measured with Beliefs about Medicines Questionnaire (BMQ) [
22]. The BMQ is a validated questionnaire. It is divided in two parts, the BMQ general and the BMQ specific. BMQ general measures the patient's beliefs and attitude towards medicines in general. The BMQ specific is specified for erlotinib.
6. Patient characteristics: date of birth, gender, socio-economic status and smoking (current smoking and never/previous smoking).
7. Dose adjustments by the patient. Dose adjustments introduced by the doctor will be derived from the patient file.
8. Co-medication.
9. Discontinuation and reasons for discontinuation. Discontinuation is also derived from the patient file.
Electronic monitoring system
Adherence will be measured using a medication event monitoring system (MEMS) [
44]. Electronic monitoring systems use standard pill containers with a small electronic processor in the cap, to record the timing and frequency of bottle openings. Compared to other methods (e.g., assay, self-report, collateral report, prescription refills), electronic monitoring captures more of the dynamics of medication-taking behaviour [
45]. In this study the Evalan Real Time Medication Monitoring (RTMM) is used.
Blood sample and laboratory test
A plasma sample will be collected at visits of the patient at week 3-4, 8-9 and 15-16. This blood sample will be drawn simultaneously with the regular treatment's related blood sampling. At these visits patients are asked when they had their last meal and at what time they took their last erlotinib medication. Patients are supposed to take erlotinib at least one hour before or two hours after a meal [
31]. Adherence to the instruction will be taken into account in the analysis of the study results.
Apart from that, the time of the blood sample will be documented. Plasma concentrations of erlotinib will be analyzed by LC-MS/MS. The pharmacokinetic parameters AUC, C
max and C
through will be derived using the pharmacokinetic model as described by Lu et al [
36]. The concentration ratio (CR) is defined as the measured erlotinib concentration divided by the mean population erlotinib concentration that is predicted by the model. To calculate the AUC, C
max, C
through and CR the following covariates are measured and used as input for the model: gender, serum albumin, serum total bilirubin, serum α1-acid glycoprotein, calculated creatinine clearance and smoking status [
36]. The calculated AUC, C
max, C
through and CR will be compared with the data on adherence from the questionnaires and the electronic monitoring system to study the relationship between adherence and the plasma concentration of erlotinib.
Patients are asked about their co-medication in the questionnaires. The data on co-administration of inhibitors of CYP1A2 and CYP3A4, inductors of CYP3A4 and antacids will be examined as covariables.